title: Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis.
abstract: We investigated soluble vascular cell adhesion molecule-1 (sVCAM) levels and MRI lesions over 24 weeks in 15 Relapsing Remitting MS (RRMS) patients randomized prospectively to receive once-weekly (qw) IFN-beta-1a 30 mug intramuscularly (IM) (Group I, 8 patients) or three-times-weekly (tiw) IFN-beta-1a 44 mug subcutaneously (SC) (Group II, 7 patients). Both groups demonstrated a significant increase in sVCAM during treatment when compared to pre-treatment levels. Patients on IFN-beta-1a 44 mug SC tiw had a significant (p<0.0001) mean increase in sVCAM of 321.9 ng/ml which was significantly greater (p<0.0001) than with IFN-beta-1a 30 mug IM qw (68.6 ng/ml). There was a negative correlation between combined unique (CU) MRI lesions and sVCAM levels within the IFN-beta-1a 44 mug SC tiw group (slope=-0.00106, p=0.009). We postulate that the mode of action of IFN-beta therapy in MS may involve the induction of an increase in sVCAM. sVCAM could bind VLA-4 on T-cells and intercept their adhesion to the blood brain barrier (BBB). This mechanism is consistent with the observed clinical effect of IFN-beta in reducing MRI contrast enhancing lesions.
authors.affiliation: University of Maryland School of Medicine, Department of Neurology, Baltimore, MD, USA.
authors.forename: J
authors.initials: J
authors.lastname: Graber
authors.forename: M
authors.initials: M
authors.lastname: Zhan
authors.forename: D
authors.initials: D
authors.lastname: Ford
authors.forename: F
authors.initials: F
authors.lastname: Kursch
authors.forename: G
authors.initials: G
authors.lastname: Francis
authors.forename: C
authors.initials: C
authors.lastname: Bever
authors.forename: H
authors.initials: H
authors.lastname: Panitch
authors.forename: P A
authors.initials: PA
authors.lastname: Calabresi
authors.forename: S
authors.initials: S
authors.lastname: Dhib-Jalbut
mesh_terms: D000704:Analysis of Variance; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004333:Drug Administration Routes; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage* / Q000627:therapeutic use; D016014:Linear Models; D008279:Magnetic Resonance Imaging / Q000379:methods; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009460:Neurologic Examination; D011446:Prospective Studies; D013997:Time Factors; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism*
chemical_list: D019010:Vascular Cell Adhesion Molecule-1; D016899:Interferon-beta; D000068556:Interferon beta-1a